BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H, Goldberg M. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23:4330-4337. [PMID: 15781882 DOI: 10.1200/jco.2005.05.017] [Cited by in Crossref: 324] [Cited by in F6Publishing: 129] [Article Influence: 19.1] [Reference Citation Analysis]
Number Citing Articles
1 Nusrath S, Thammineedi SR, Raju KVVN, Patnaik SC, Saksena AR, Karthik J, Basude M, Kumar J P, Shukla S, Rao VB, Kumar C K, Gujjuru S, Tewani R, Rushdie T, Sudhir R, Smith LM, Are C. Factors associated with pathologic complete response following neoadjuvant chemoradiation and esophagectomy for carcinoma of esophagus and gastroesophageal junction. J Surg Oncol 2022. [PMID: 36129433 DOI: 10.1002/jso.27103] [Reference Citation Analysis]
2 Wang H, Li S, Liu T, Chen J, Dang J. Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis. Front Immunol 2022;13:998620. [DOI: 10.3389/fimmu.2022.998620] [Reference Citation Analysis]
3 Song K, Gu B, Ma C, Wang B, Wang N, Yu R, Chen H, Zhuo Z. Epithelial-Mesenchymal Transition Gene Signature Is Associated with Neoadjuvant Chemoradiotherapy Resistance and Prognosis of Esophageal Squamous Cell Carcinoma. Disease Markers 2022;2022:1-14. [DOI: 10.1155/2022/3534433] [Reference Citation Analysis]
4 Qian D, Chen X, Shang X, Wang Y, Tang P, Han D, Jiang H, Chen C, Zhao G, Zhou D, Cao F, Er P, Zhang W, Li X, Zhang T, Zhang B, Guan Y, Wang J, Yuan Z, Yu Z, Wang P, Pang Q. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradiation finished: A phase II random. Radiother Oncol 2022:S0167-8140(22)04176-7. [PMID: 35764191 DOI: 10.1016/j.radonc.2022.06.015] [Reference Citation Analysis]
5 Wang R, Zhou X, Liu T, Lin S, Wang Y, Deng X, Wang W. Gross Tumor Volume Predicts Survival and Pathological Complete Response of Locally Advanced Esophageal Cancer After Neoadjuvant Chemoradiotherapy. Front Oncol 2022;12:898383. [DOI: 10.3389/fonc.2022.898383] [Reference Citation Analysis]
6 Zhang P, Hou X, Cai B, Yu W, Chen J, Huang X, Li Y, Zeng M, Ren Z, Gabriel E, Qu B, Liu F. Efficacy and safety of combined treatment with pembrolizumab in patients with locally advanced or metastatic esophageal squamous cell carcinoma in the real world. Ann Transl Med 2022;10:708. [PMID: 35845479 DOI: 10.21037/atm-22-2779] [Reference Citation Analysis]
7 Kamarajah SK, Markar SR, Phillips AW, Kunene V, Fackrell D, Salti GI, Dahdaleh FS, Griffiths EA. Survival benefit of adjuvant chemotherapy following neoadjuvant therapy and oesophagectomy in oesophageal adenocarcinoma. European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.05.014] [Reference Citation Analysis]
8 Tustumi F, Albenda DG, Sallum RAA, Nahas SC, Ribeiro Junior U, Buchpiguel CA, Cecconello I, Duarte PS. 18F-FDG-PET/CT-measured parameters as potential predictors of residual disease after neoadjuvant chemoradiotherapy in patients with esophageal carcinoma. Radiol Bras. [DOI: 10.1590/0100-3984.2021.0135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Alvarado CE, Kapcio KC, Lada MJ, Linden PA, Towe CW, Worrell SG. The effect of diabetes on pathologic complete response among patients with esophageal cancer. Seminars in Thoracic and Cardiovascular Surgery 2022. [DOI: 10.1053/j.semtcvs.2021.10.016] [Reference Citation Analysis]
10 Hong ZN, Weng K, Peng K, Chen Z, Lin J, Kang M. Neoadjuvant Immunotherapy Combined Chemotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Study. Front Oncol 2021;11:797426. [PMID: 34970498 DOI: 10.3389/fonc.2021.797426] [Reference Citation Analysis]
11 Zhang Z, Hong ZN, Xie S, Lin W, Lin Y, Zhu J, Yang X, Lin Z, Lin J, Kang M. Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1). Ann Transl Med 2021;9:1623. [PMID: 34926667 DOI: 10.21037/atm-21-5381] [Reference Citation Analysis]
12 Nehlsen AD, Lehrer EJ, Resende-Salgado L, Rosenzweig KE, Buckstein M. Comparison of Pathologic Complete Response Rates and Oncologic Outcomes in Patients With Surgically Resectable Esophageal Cancer Treated With Neoadjuvant Chemoradiation to 50.4 Gy vs 41.4 Gy. Cureus 2021;13:e19233. [PMID: 34877210 DOI: 10.7759/cureus.19233] [Reference Citation Analysis]
13 Bhattacharyya T, Arunsingh M, Chakraborty S, Harilal V, Sasidharan R, Saha S, Thambudorai R, Roy B, Banerjee S, Roy P, Ray S, Mallick I. Can the CROSS protocol be safely implemented in real world scenario with broader eligibility criteria? Experience from a tertiary care centre in India. Ecancermedicalscience 2021;15:1291. [PMID: 34824614 DOI: 10.3332/ecancer.2021.1291] [Reference Citation Analysis]
14 Shen J, Kong M, Yang H, Jin K, Chen Y, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, Zhang X, Li Q, Wang G, Mao T, Guo X, Lin T, Liu M, Ma D, Ye M, Wang C, Wang Z, Brunelli A, Cerfolio RJ, D'Journo XB, Fernando HC, Lordick F, Fu J, Chen B, Zhu C; written on behalf of the AME Thoracic Surgery Collaborative Group. Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010). Ann Transl Med 2021;9:1516. [PMID: 34790722 DOI: 10.21037/atm-21-3331] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Devos G, Devlies W, De Meerleer G, Baldewijns M, Gevaert T, Moris L, Milonas D, Van Poppel H, Berghen C, Everaerts W, Claessens F, Joniau S. Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. Nat Rev Urol 2021. [PMID: 34526701 DOI: 10.1038/s41585-021-00514-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Choi Y, Choi JY, Hong TH, Choi YL, Oh D, Woo SY, Shim YM, Zo JI, Kim HK, Lee KS. Trimodality therapy for locally advanced esophageal squamous cell carcinoma: the role of volume-based PET/CT in patient management and prognostication. Eur J Nucl Med Mol Imaging 2021. [PMID: 34365522 DOI: 10.1007/s00259-021-05487-w] [Reference Citation Analysis]
17 Li SH, Chen YH, Lu HI, Lo CM, Huang CC, Wang YM, Huang EY. Galectin-1 Expression Is Associated with the Response and Survival Following Preoperative Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma. Cancers (Basel) 2021;13:3147. [PMID: 34201887 DOI: 10.3390/cancers13133147] [Reference Citation Analysis]
18 Xie CY, Hu YH, Ho JW, Han LJ, Yang H, Wen J, Lam KO, Wong IY, Law SY, Chiu KW, Fu JH, Vardhanabhuti V. Using Genomics Feature Selection Method in Radiomics Pipeline Improves Prognostication Performance in Locally Advanced Esophageal Squamous Cell Carcinoma-A Pilot Study. Cancers (Basel) 2021;13:2145. [PMID: 33946826 DOI: 10.3390/cancers13092145] [Reference Citation Analysis]
19 Wang J, Yu P, Luo J, Sun Z, Yu J, Wang J. Transcriptomic and microRNA Expression Profiles Identify Biomarkers for Predicting Neo-Chemoradiotherapy Response in Esophageal Squamous Cell Carcinomas (ESCC). Front Pharmacol 2021;12:626972. [PMID: 33935718 DOI: 10.3389/fphar.2021.626972] [Reference Citation Analysis]
20 Nagaki Y, Motoyama S, Sato Y, Wakita A, Fujita H, Sasaki Y, Imai K, Minamiya Y. SUVmax reduction predicts long-term survival in patients of non-pCR both in the tumor and lymph nodes after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma. World J Surg Oncol 2021;19:105. [PMID: 33836789 DOI: 10.1186/s12957-021-02208-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Solomon D, Abbas M, Feferman Y, Haddad R, Perl G, Kundel Y, Morgenstern S, Menasherov N, Kashtan H. Signet Ring Cell Features are Associated with Poor Response to Neoadjuvant Treatment and Dismal Survival in Patients with High-Grade Esophageal Adenocarcinoma. Ann Surg Oncol 2021;28:4929-40. [PMID: 33709175 DOI: 10.1245/s10434-021-09644-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Chi D, Chen B, Guo S, Bai K, Ma H, Hu Y, Li Q, Zhu Y. Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy. Aging (Albany NY) 2021;13:8408-20. [PMID: 33713398 DOI: 10.18632/aging.202652] [Reference Citation Analysis]
23 Rocha-Filho DR, Peixoto RD, Weschenfelder RF, Rego JFM, Riechelmann R, Coutinho AK, Fernandes GS, Jacome AA, Andrade AC, Murad AM, Mello CAL, Miguel DSCG, Gomes DBD, Racy DJ, Moraes ED, Akaishi EH, Carvalho ES, Mello ES, Filho FM, Coimbra FJF, Capareli FC, Arruda FF, Vieira FMAC, Takeda FR, Cotti GCC, Pereira GLS, Paulo GA, Ribeiro HSC, Lourenco LG, Crosara M, Toneto MG, Oliveira MB, de Lourdes Oliveira M, Begnami MD, Forones NM, Yagi O, Ashton-Prolla P, Aguillar PB, Amaral PCG, Hoff PM, Araujo RLC, Di Paula Filho RP, Gansl RC, Gil RA, Pfiffer TEF, Souza T, Ribeiro U Jr, Jesus VHF, Costa WL Jr, Prolla G. Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of oesophageal cancer. Ecancermedicalscience 2021;15:1195. [PMID: 33889204 DOI: 10.3332/ecancer.2021.1195] [Reference Citation Analysis]
24 Han S, Kim YI, Woo S, Kim TH, Ryu JS. Prognostic and predictive values of interim 18F-FDG PET during neoadjuvant chemoradiotherapy for esophageal cancer: a systematic review and meta-analysis. Ann Nucl Med 2021;35:447-57. [PMID: 33471289 DOI: 10.1007/s12149-021-01583-x] [Reference Citation Analysis]
25 Lavery A, Turkington RC. Transcriptomic biomarkers for predicting response to neoadjuvant treatment in oesophageal cancer. Gastroenterol Rep (Oxf) 2020;8:411-24. [PMID: 33442473 DOI: 10.1093/gastro/goaa065] [Reference Citation Analysis]
26 Boniface C, Deig C, Halsey C, Kelley T, Heskett MB, Thomas CR Jr, Spellman PT, Nabavizadeh N. The Feasibility of Patient-Specific Circulating Tumor DNA Monitoring throughout Multi-Modality Therapy for Locally Advanced Esophageal and Rectal Cancer: A Potential Biomarker for Early Detection of Subclinical Disease. Diagnostics (Basel) 2021;11:73. [PMID: 33466369 DOI: 10.3390/diagnostics11010073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Ahmad SZ, Battoo AJ, Haji AG, Naveed S, Qurieshi MA, Mir AW, Malik TR. Patterns of Failure After Trimodal Treatment in Esophageal Squamous Cell Carcinoma: Initial Experiences from a High-Risk Endemic Area. Indian J Surg Oncol 2020;11:360-6. [PMID: 33013111 DOI: 10.1007/s13193-020-01164-w] [Reference Citation Analysis]
28 Huang R, Guo H, Chen J, Zhai T, Chen J, Lin K, Chen Z, Li D, Chen C. Intratreatment Tumor Volume Change During Definitive Chemoradiotherapy is Predictive for Treatment Outcome of Patients with Esophageal Carcinoma. Cancer Manag Res 2020;12:7331-9. [PMID: 32884347 DOI: 10.2147/CMAR.S246500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Hu Y, Xie C, Yang H, Ho JWK, Wen J, Han L, Chiu KWH, Fu J, Vardhanabhuti V. Assessment of Intratumoral and Peritumoral Computed Tomography Radiomics for Predicting Pathological Complete Response to Neoadjuvant Chemoradiation in Patients With Esophageal Squamous Cell Carcinoma. JAMA Netw Open. 2020;3:e2015927. [PMID: 32910196 DOI: 10.1001/jamanetworkopen.2020.15927] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
30 Kotsafti A, Scarpa M, Cavallin F, Fassan M, Salmaso R, Porzionato A, Saadeh L, Cagol M, Alfieri R, Castoro C, Rugge M, Castagliuolo I, Scarpa M. Immune surveillance activation after neoadjuvant therapy for esophageal adenocarcinoma and complete response. Oncoimmunology 2020;9:1804169. [PMID: 32923165 DOI: 10.1080/2162402X.2020.1804169] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 DeCesaris CM, Berger M, Choi JI, Carr SR, Burrows WM, Regine WF, Simone CB 2nd, Molitoris JK. Pathologic complete response (pCR) rates and outcomes after neoadjuvant chemoradiotherapy with proton or photon radiation for adenocarcinomas of the esophagus and gastroesophageal junction. J Gastrointest Oncol 2020;11:663-73. [PMID: 32953150 DOI: 10.21037/jgo-20-205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Lindenmann J, Fediuk M, Fink-Neuboeck N, Porubsky C, Pichler M, Brcic L, Anegg U, Balic M, Dandachi N, Maier A, Smolle M, Smolle J, Smolle-Juettner FM. Hazard Curves for Tumor Recurrence and Tumor-Related Death Following Esophagectomy for Esophageal Cancer. Cancers (Basel) 2020;12:E2066. [PMID: 32726927 DOI: 10.3390/cancers12082066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Zhao Z, Zhang Y, Wang X, Geng X, Zhu L, Li M. Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy. Cancer Med 2020;9:5881-8. [PMID: 32627960 DOI: 10.1002/cam4.3273] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
34 Saeki H, Sohda M, Sakai M, Sano A, Shirabe K. Role of surgery in multidisciplinary treatment strategies for locally advanced esophageal squamous cell carcinoma. Ann Gastroenterol Surg 2020;4:490-7. [PMID: 33005843 DOI: 10.1002/ags3.12364] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
35 Shang QX, Yang YS, Gu YM, Zeng XX, Zhang HL, Hu WP, Wang WP, Chen LQ, Yuan Y. Timing of surgery after neoadjuvant chemoradiotherapy affects oncologic outcomes in patients with esophageal cancer. World J Gastrointest Oncol 2020; 12(6): 687-698 [PMID: 32699583 DOI: 10.4251/wjgo.v12.i6.687] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Zhao Z, Zhang Y, Wang X, Wang P, Geng X, Zhu L, Li M. The Prognostic Significance of Metastatic Nodal Size in Non-surgical Patients With Esophageal Squamous Cell Carcinoma. Front Oncol 2020;10:523. [PMID: 32373526 DOI: 10.3389/fonc.2020.00523] [Reference Citation Analysis]
37 Lopez A, Harada K, Chen HC, Bhutani MS, Weston B, Lee JH, Maru DM, Chin FW, Rogers JE, Thomas I, Amlashi FG, Blum-Murphy MA, Rice DC, Zhao M, Hofstetter WL, Nguyen Q, Ajani JA. Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients. Medicine (Baltimore) 2020;99:e19295. [PMID: 32118743 DOI: 10.1097/MD.0000000000019295] [Reference Citation Analysis]
38 Maffazzioli L, Zilio MB, Klamt AL, Duarte JA, Mazzini GS, Campos VJ, Chedid MF, Gurski RR. ADC as a predictor of pathologic response to neoadjuvant therapy in esophageal cancer: a systematic review and meta-analysis. Eur Radiol 2020;30:3934-42. [PMID: 32157409 DOI: 10.1007/s00330-020-06723-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Groth SS, Burt BM. Percentage of tumor-infiltrating lymphocytes after chemoradiation therapy for locally advanced esophageal squamous cell carcinoma: a biomarker for pathological response rates and cancer-specific survival? Ann Transl Med 2019;7:S310. [PMID: 32016029 DOI: 10.21037/atm.2019.10.25] [Reference Citation Analysis]
40 Azad TD, Chaudhuri AA, Fang P, Qiao Y, Esfahani MS, Chabon JJ, Hamilton EG, Yang YD, Lovejoy A, Newman AM, Kurtz DM, Jin M, Schroers-Martin J, Stehr H, Liu CL, Hui AB, Patel V, Maru D, Lin SH, Alizadeh AA, Diehn M. Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer. Gastroenterology 2020;158:494-505.e6. [PMID: 31711920 DOI: 10.1053/j.gastro.2019.10.039] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 13.3] [Reference Citation Analysis]
41 Zhao Y, Wang N, Zhang X, Liu H, Yang S. LncRNA ZEB1-AS1 down-regulation suppresses the proliferation and invasion by inhibiting ZEB1 expression in oesophageal squamous cell carcinoma. J Cell Mol Med 2019;23:8206-18. [PMID: 31638344 DOI: 10.1111/jcmm.14692] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
42 Fassan M, Cavallin F, Guzzardo V, Kotsafti A, Scarpa M, Cagol M, Chiarion-Sileni V, Maria Saadeh L, Alfieri R, Castagliuolo I, Rugge M, Castoro C, Scarpa M. PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus. Cancer Med 2019;8:6036-48. [PMID: 31429521 DOI: 10.1002/cam4.2359] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
43 Veeranki OL, Tong Z, Dokey R, Mejia A, Zhang J, Qiao Y, Singh PK, Katkhuda R, Mino B, Tailor R, Canales JR, Bassett R, Ajani J, Wu JY, Kopetz S, Blum M, Hofstetter W, Tetzlaff M, Krishnan S, Lin SH, Maru D. Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma. Oncotarget 2019;10:4703-18. [PMID: 31384397 DOI: 10.18632/oncotarget.27095] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
44 Wang Q, Cao B, Chen J, Li C, Tan L, Zhang W, Lv J, Li X, Xiao M, Lin Y, Lang J, Li T, Xiao Z. Tumor Compactness based on CT to predict prognosis after multimodal treatment for esophageal squamous cell carcinoma. Sci Rep 2019;9:10497. [PMID: 31324827 DOI: 10.1038/s41598-019-46899-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
45 Chen M, Liu P, Chen Y, Chen Z, Shen M, Liu X, Li X, Lin Y, Yang R, Ni W, Zhou X, Zhang L, Tian Y, Chen J. Primary tumor regression patterns in esophageal squamous cell cancer treated with definitive chemoradiotherapy and implications for surveillance schemes. Cancer Manag Res. 2019;11:3361-3369. [PMID: 31114372 DOI: 10.2147/cmar.s198524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
46 McKay RR, Ye H, Xie W, Lis R, Calagua C, Zhang Z, Trinh QD, Chang SL, Harshman LC, Ross AE, Pienta KJ, Lin DW, Ellis WJ, Montgomery B, Chang P, Wagner AA, Bubley GJ, Kibel AS, Taplin ME. Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. J Clin Oncol 2019;37:923-31. [PMID: 30811282 DOI: 10.1200/JCO.18.01777] [Cited by in Crossref: 35] [Cited by in F6Publishing: 14] [Article Influence: 11.7] [Reference Citation Analysis]
47 Vollenbrock SE, Voncken FEM, van Dieren JM, Lambregts DMJ, Maas M, Meijer GJ, Goense L, Mook S, Hartemink KJ, Snaebjornsson P, Ter Beek LC, Verheij M, Aleman BMP, Beets-Tan RGH, Bartels-Rutten A. Diagnostic performance of MRI for assessment of response to neoadjuvant chemoradiotherapy in oesophageal cancer. Br J Surg 2019;106:596-605. [PMID: 30802305 DOI: 10.1002/bjs.11094] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
48 Roh S, Iannettoni MD, Keech J, Arshava EV, Swatek A, Zimmerman MB, Weigel RJ, Parekh KR. Timing of Esophagectomy after Neoadjuvant Chemoradiation Therapy Affects the Incidence of Anastomotic Leaks. Korean J Thorac Cardiovasc Surg 2019;52:1-8. [PMID: 30834211 DOI: 10.5090/kjtcs.2019.52.1.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
49 Nusrath S, Thammineedi SR, Vijaya Narsimha Raju KV, Patnaik SC, Pawar S, Santa A, Rajappa SJ, Mallavarapu KM, Raju K, Murthy S. Short-term Outcomes in Patients with Carcinoma of the Esophagus and Gastroesophageal Junction Receiving Neoadjuvant Chemotherapy or Chemoradiation before Surgery. A Prospective Study. Rambam Maimonides Med J 2019;10. [PMID: 29993360 DOI: 10.5041/RMMJ.10339] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
50 Xie K, Liu S, Liu J. Nomogram predicts survival benefit for non- metastatic esophageal cancer patients who underwent preoperative radiotherapy. Cancer Manag Res 2018;10:3657-68. [PMID: 30271214 DOI: 10.2147/CMAR.S165168] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
51 Hamai Y, Hihara J, Emi M, Furukawa T, Murakami Y, Nishibuchi I, Ibuki Y, Yamakita I, Kurokawa T, Nagata Y, Okada M. Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery. World J Surg 2018;42:1496-505. [PMID: 29030675 DOI: 10.1007/s00268-017-4283-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
52 Heethuis SE, Goense L, van Rossum PSN, Borggreve AS, Mook S, Voncken FEM, Bartels-Rutten A, Aleman BMP, van Hillegersberg R, Ruurda JP, Meijer GJ, Lagendijk JJW, van Lier ALHMW. DW-MRI and DCE-MRI are of complementary value in predicting pathologic response to neoadjuvant chemoradiotherapy for esophageal cancer. Acta Oncol 2018;57:1201-8. [PMID: 29781342 DOI: 10.1080/0284186X.2018.1473637] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
53 Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, Lordick F, D'Journo XB, Cerfolio RJ, Korst RJ, Novoa NM, Swanson SJ, Brunelli A, Ismail M, Fernando HC, Zhang X, Li Q, Wang G, Chen B, Mao T, Kong M, Guo X, Lin T, Liu M, Fu J; AME Thoracic Surgery Collaborative Group. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. J Clin Oncol. 2018;36:2796-2803. [PMID: 30089078 DOI: 10.1200/jco.2018.79.1483] [Cited by in Crossref: 266] [Cited by in F6Publishing: 268] [Article Influence: 66.5] [Reference Citation Analysis]
54 Soror T, Kho G, Zhao KL, Ismail M, Badakhshi H. Impact of pathological complete response following neoadjuvant chemoradiotherapy in esophageal cancer. J Thorac Dis 2018;10:4069-76. [PMID: 30174850 DOI: 10.21037/jtd.2018.06.85] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
55 Taylor Ripley R, Surman DR, Diggs LP, Trepel JB, Lee MJ, Ryan J, Davis JL, Steinberg SM, Hernandez JM, Hoang C, Kenney CM, Bond CD, Kunst TF, Letai A, Schrump DS. Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy. BMC Gastroenterol 2018;18:94. [PMID: 29933761 DOI: 10.1186/s12876-018-0823-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
56 Zhao Y, Ma K, Yang S, Zhang X, Wang F, Zhang X, Liu H, Fan Q. MicroRNA-125a-5p enhances the sensitivity of esophageal squamous cell carcinoma cells to cisplatin by suppressing the activation of the STAT3 signaling pathway. Int J Oncol 2018;53:644-58. [PMID: 29767234 DOI: 10.3892/ijo.2018.4409] [Cited by in Crossref: 8] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
57 Barbetta A, Nobel TB, Sihag S, Hsu M, Tan KS, Bains MS, Isbell JM, Janjigian YY, Wu AJ, Bott MJ, Jones DR, Molena D. Neutrophil to Lymphocyte Ratio as Predictor of Treatment Response in Esophageal Squamous Cell Cancer. Ann Thorac Surg 2018;106:864-71. [PMID: 29738752 DOI: 10.1016/j.athoracsur.2018.04.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
58 Chiu TJ, Lu HI, Chen CH, Huang WT, Wang YM, Lin WC, Li SH. Osteopontin Expression Is Associated with the Poor Prognosis in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy. Biomed Res Int 2018;2018:9098215. [PMID: 29854808 DOI: 10.1155/2018/9098215] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
59 Deng W, Wang Q, Xiao Z, Tan L, Yang Z, Zhou Z, Zhang H, Chen D, Feng Q, Liang J, Li Y, He J, Gao S, Sun K, Cheng G, Liu X, Fang D, Xue Q, Mao Y, Wang D, Li J. A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcinoma: a retrospective analysis. Oncotarget 2017;8:41102-12. [PMID: 28456788 DOI: 10.18632/oncotarget.17062] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
60 Macomber MW, Bowen SR, Gopan O, Yeung R, Apisarnthanarax S, Zeng J, Patel S. Heart Dose and Outcomes in Radiation Treatment for Esophageal Cancer. Cureus 2018;10:e2378. [PMID: 29805947 DOI: 10.7759/cureus.2378] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
61 Harada K, Mizrak Kaya D, Lopez A, Baba H, Ajani JA. Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma. Ann Transl Med 2018;6:80. [PMID: 29666803 DOI: 10.21037/atm.2017.10.28] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
62 Park IH, Kim JY. Surveillance or resection after chemoradiation in esophageal cancer. Ann Transl Med 2018;6:82. [PMID: 29666805 DOI: 10.21037/atm.2017.12.16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
63 Chan CM, Lai KKY, Ng EKO, Kiang MN, Kwok TWH, Wang HK, Chan KW, Law TT, Tong DK, Chan KT, Lee NP, Law S. Serum microRNA-193b as a promising biomarker for prediction of chemoradiation sensitivity in esophageal squamous cell carcinoma patients. Oncol Lett 2018;15:3273-80. [PMID: 29435069 DOI: 10.3892/ol.2017.7698] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
64 Luu C, Thapa R, Woo K, Coppola D, Almhanna K, Pimiento JM, Chen DT, Marquez DD, Hodul PJ. Does histology really influence gastric cancer prognosis? J Gastrointest Oncol 2017;8:1026-36. [PMID: 29299363 DOI: 10.21037/jgo.2017.09.08] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
65 Samuels SE, Stenmark MH, Lee JY, McHugh JB, Hayman JA, Orringer MB, Urba SG, Sun L, Xie C, Kong FM, Cuneo KC. Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes. Adv Radiat Oncol 2017;2:308-15. [PMID: 29114597 DOI: 10.1016/j.adro.2017.05.003] [Reference Citation Analysis]
66 Xu C, Xi M, Komaki R, Balter PA, Huang M, Hobbs BP, Wang L, Lin SH. Dosimetric and clinical outcomes after volumetric modulated arc therapy for carcinoma of the thoracic esophagus. Adv Radiat Oncol 2017;2:325-32. [PMID: 29114599 DOI: 10.1016/j.adro.2017.03.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
67 Boland PM, Meyer JE, Berger AC, Cohen SJ, Neuman T, Cooper HS, Olszanski AJ, Davey M, Cheng JD, Lebenthal A, Burtness BA, Scott WJ, Astsaturov IA. Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. Am J Clin Oncol. 2017;40:393-398. [PMID: 26986978 DOI: 10.1097/coc.0000000000000171] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
68 Wadhwa R, Wang X, Baladandayuthapani V, Liu B, Shiozaki H, Shimodaira Y, Lin Q, Elimova E, Hofstetter WL, Swisher SG, Rice DC, Maru DM, Kalhor N, Bhutani MS, Weston B, Lee JH, Skinner HD, Scott AW, Kaya DM, Harada K, Berry D, Song S, Ajani JA. Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. Br J Cancer 2017;117:648-55. [PMID: 28728163 DOI: 10.1038/bjc.2017.225] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
69 Lv HW, Li Y, Zhou MH, Cheng JW, Xing WQ. Remnant lymph node metastases after neoadjuvant therapy and surgery in patients with pathologic T0 esophageal carcinoma impact on prognosis: A systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e7342. [PMID: 28658150 DOI: 10.1097/MD.0000000000007342] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
70 den Bakker CM, Smit JK, Bruynzeel AME, van Grieken NCT, Daams F, Derks S, Cuesta MA, Plukker JTM, van der Peet DL. Non responders to neoadjuvant chemoradiation for esophageal cancer: why better prediction is necessary. J Thorac Dis 2017;9:S843-50. [PMID: 28815082 DOI: 10.21037/jtd.2017.06.123] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
71 Harada K, Mizrak Kaya D, Baba H, Ajani JA. Recent advances in preoperative management of esophageal adenocarcinoma. F1000Res 2017;6:501. [PMID: 28491289 DOI: 10.12688/f1000research.10794.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
72 Palmarocchi MC, Balzarotti Canger RC, Saletti P. Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report. Oncol Lett 2017;13:4445-52. [PMID: 28588713 DOI: 10.3892/ol.2017.6026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
73 Li Z, Zhang P, Ma Q, Wang D, Zhou T. Cisplatin-based chemoradiotherapy with 5-fluorouracil or pemetrexed in patients with locally advanced, unresectable esophageal squamous cell carcinoma: A retrospective analysis. Mol Clin Oncol 2017;6:743-7. [PMID: 28515926 DOI: 10.3892/mco.2017.1222] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
74 Chen MF, Chen PT, Lu MS, Lee CP, Chen WC. Survival benefit of surgery to patients with esophageal squamous cell carcinoma. Sci Rep 2017;7:46139. [PMID: 28383075 DOI: 10.1038/srep46139] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
75 McLaren PJ, Barnes AP, Terrell WZ, Vaccaro GM, Wiedrick J, Hunter JG, Dolan JP. Specific gene expression profiles are associated with a pathologic complete response to neoadjuvant therapy in esophageal adenocarcinoma. Am J Surg 2017;213:915-20. [PMID: 28385379 DOI: 10.1016/j.amjsurg.2017.03.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
76 Gabriel E, Attwood K, Shah R, Nurkin S, Hochwald S, Kukar M. Novel Calculator to Estimate Overall Survival Benefit from Neoadjuvant Chemoradiation in Patients with Esophageal Adenocarcinoma. J Am Coll Surg 2017;224:884-894.e1. [PMID: 28147252 DOI: 10.1016/j.jamcollsurg.2017.01.043] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
77 Tu CC, Hsu PK, Chien LI, Liu WC, Huang CS, Hsieh CC, Hsu HS, Wu YC. Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery. BMC Cancer 2017;17:62. [PMID: 28103913 DOI: 10.1186/s12885-017-3063-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
78 Cho WK, Oh D, Ahn YC, Shim YM, Zo JI, Sun JM, Ahn MJ, Park K. Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery. Oncotarget 2017;8:3542-52. [PMID: 27682879 DOI: 10.18632/oncotarget.12200] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
79 Huang YC, Lu HI, Huang SC, Hsu CC, Chiu NT, Wang YM, Chiu YC, Li SH. FDG PET using SUVmax for preoperative T-staging of esophageal squamous cell carcinoma with and without neoadjuvant chemoradiotherapy. BMC Med Imaging 2017;17:1. [PMID: 28056868 DOI: 10.1186/s12880-016-0171-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
80 Huang X, Liu C, Cui Y, Zhang H, Liu Y, Zhou X, Luo J. Association between XRCC1 and ERCC1 single-nucleotide polymorphisms and the efficacy of concurrent radiochemotherapy in patients with esophageal squamous cell carcinoma. Oncol Lett. 2017;13:704-714. [PMID: 28356949 DOI: 10.3892/ol.2016.5496] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
81 Rose PG, Java JJ, Morgan MA, Alvarez-Secord A, Kesterson JP, Stehman FB, Warshal DP, Creasman WT, Hanjani P, Morris RT, Copeland LJ. Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2016;143:511-5. [PMID: 27692669 DOI: 10.1016/j.ygyno.2016.09.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
82 Elimova E, Mizrak Kaya D, Harada K, Ajani JA. Potentially Curable Cancers of the Esophagus and Stomach. Mayo Clin Proc 2016;91:1307-18. [PMID: 27594190 DOI: 10.1016/j.mayocp.2016.07.018] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
83 Cleary JM, Mamon HJ, Szymonifka J, Bueno R, Choi N, Donahue DM, Fidias PM, Gaissert HA, Jaklitsch MT, Kulke MH, Lynch TP, Mentzer SJ, Meyerhardt JA, Swanson RS, Wain J, Fuchs CS, Enzinger PC. Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer. BMC Cancer 2016;16:468. [PMID: 27412386 DOI: 10.1186/s12885-016-2485-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
84 Kuo KT, Chen CL, Chou TY, Yeh CT, Lee WH, Wang LS. Nm23H1 mediates tumor invasion in esophageal squamous cell carcinoma by regulation of CLDN1 through the AKT signaling. Oncogenesis 2016;5:e239. [PMID: 27376780 DOI: 10.1038/oncsis.2016.46] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
85 Sharma RA, Plummer R, Stock JK, Greenhalgh TA, Ataman O, Kelly S, Clay R, Adams RA, Baird RD, Billingham L, Brown SR, Buckland S, Bulbeck H, Chalmers AJ, Clack G, Cranston AN, Damstrup L, Ferraldeschi R, Forster MD, Golec J, Hagan RM, Hall E, Hanauske AR, Harrington KJ, Haswell T, Hawkins MA, Illidge T, Jones H, Kennedy AS, McDonald F, Melcher T, O'Connor JP, Pollard JR, Saunders MP, Sebag-Montefiore D, Smitt M, Staffurth J, Stratford IJ, Wedge SR; NCRI CTRad Academia-Pharma Joint Working Group. Clinical development of new drug-radiotherapy combinations. Nat Rev Clin Oncol 2016;13:627-42. [PMID: 27245279 DOI: 10.1038/nrclinonc.2016.79] [Cited by in Crossref: 135] [Cited by in F6Publishing: 134] [Article Influence: 22.5] [Reference Citation Analysis]
86 Wang X, Zhao L, Liu H, Zhong D, Liu W, Shan G, Dong F, Gao W, Bai C, Li X. A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer. Br J Cancer 2016;114:1326-33. [PMID: 27172250 DOI: 10.1038/bjc.2016.126] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
87 Yip SS, Coroller TP, Sanford NN, Mamon H, Aerts HJ, Berbeco RI. Relationship between the Temporal Changes in Positron-Emission-Tomography-Imaging-Based Textural Features and Pathologic Response and Survival in Esophageal Cancer Patients. Front Oncol 2016;6:72. [PMID: 27066454 DOI: 10.3389/fonc.2016.00072] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
88 Chen J, Yang H, Wen J, Luo K, Liu Q, Huang Y, Zheng Y, Tan Z, Huang Q, Fu J. NHE9 induces chemoradiotherapy resistance in esophageal squamous cell carcinoma by upregulating the Src/Akt/β-catenin pathway and Bcl-2 expression. Oncotarget 2015;6:12405-20. [PMID: 25915159 DOI: 10.18632/oncotarget.3618] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
89 Shaikh T, Zaki MA, Dominello MM, Handorf E, Konski AA, Cohen SJ, Shields A, Philip P, Meyer JE. Patterns and predictors of failure following tri-modality therapy for locally advanced esophageal cancer. Acta Oncol 2016;55:303-8. [PMID: 26581671 DOI: 10.3109/0284186X.2015.1110252] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
90 Brescia AA, Broderick SR, Crabtree TD, Puri V, Musick JF, Bell JM, Kreisel D, Krupnick AS, Patterson GA, Meyers BF. Adjuvant Therapy for Positive Nodes After Induction Therapy and Resection of Esophageal Cancer. Ann Thorac Surg 2016;101:200-8; discussion 208-10. [PMID: 26507424 DOI: 10.1016/j.athoracsur.2015.09.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
91 Elimova E, Wang X, Etchebehere E, Shiozaki H, Shimodaira Y, Wadhwa R, Planjery V, Charalampakis N, Blum MA, Hofstetter W, Lee JH, Weston BR, Bhutani MS, Rogers JE, Maru D, Skinner HD, Macapinlac HA, Ajani JA. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. Eur J Cancer 2015;51:2545-52. [PMID: 26321501 DOI: 10.1016/j.ejca.2015.07.044] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
92 Hamai Y, Hihara J, Taomoto J, Yamakita I, Ibuki Y, Okada M. Hemoglobin level influences tumor response and survival after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma. World J Surg 2014;38:2046-51. [PMID: 24615604 DOI: 10.1007/s00268-014-2486-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
93 Zheng YZ, Zhao W, Hu Y, Ding-Lin XX, Wen J, Yang H, Liu QW, Luo KJ, Huang QY, Chen JY, Fu JH. Aggressive surgical resection does not improve survival in operable esophageal squamous cell carcinoma with N2-3 status. World J Gastroenterol 2015; 21(28): 8644-8652 [PMID: 26229406 DOI: 10.3748/wjg.v21.i28.8644] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
94 Wang Q, Yu S, Xiao Z, Liu X, Zhang W, Zhang X, He J, Sun K, Xu T, Feng Q, Zhou Z, Wang L, Yin W. Residual lymph node status is an independent prognostic factor in esophageal squamous cell Carcinoma with pathologic T0 after preoperative radiotherapy. Radiat Oncol 2015;10:142. [PMID: 26159510 DOI: 10.1186/s13014-015-0450-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
95 Hsu FM, Cheng JC, Chang YL, Lee JM, Koong AC, Chuang EY. Circulating mRNA Profiling in Esophageal Squamous Cell Carcinoma Identifies FAM84B As A Biomarker In Predicting Pathological Response to Neoadjuvant Chemoradiation. Sci Rep 2015;5:10291. [PMID: 25980316 DOI: 10.1038/srep10291] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
96 Chao YK, Yeh CJ, Lee MH, Wen YW, Chang HK, Tseng CK, Liu YH. Factors associated with false-negative endoscopic biopsy results after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma. Medicine (Baltimore) 2015;94:e588. [PMID: 25715265 DOI: 10.1097/MD.0000000000000588] [Cited by in Crossref: 6] [Article Influence: 0.9] [Reference Citation Analysis]
97 Kim YH, Song SY, Shim HJ, Chung WK, Ahn SJ, Yoon MS, Jeong JU, Song JY, Nam TK. Treatment outcomes of neoadjuvant concurrent chemoradiotherapy followed by esophagectomy for patients with esophageal cancer. Radiat Oncol J 2015;33:12-20. [PMID: 25874173 DOI: 10.3857/roj.2015.33.1.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
98 Neishaboori N, Wadhwa R, Nogueras-González GM, Elimova E, Shiozaki H, Sudo K, Charalampakis N, Hiremath A, Lee JH, Bhutani MS, Weston B, Blum MA, Rogers JE, Garris JL, Rice DC, Komaki R, Swisher SG, Skinner HD, Hofstetter WL, Ajani JA. Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications. Oncology 2015;89:65-9. [PMID: 25765719 DOI: 10.1159/000371889] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
99 Saeki H, Nakashima Y, Zaitsu Y, Tsuda Y, Kasagi Y, Ando K, Imamura Y, Ohgaki K, Ito S, Kimura Y, Egashira A, Oki E, Morita M, Maehara Y. Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Surg Today 2016;46:261-7. [PMID: 25740123 DOI: 10.1007/s00595-015-1144-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
100 Lin SH, Wang J, Allen PK, Correa AM, Maru DM, Swisher SG, Hofstetter WL, Liao Z, Ajani JA. A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. J Gastrointest Oncol 2015;6:45-52. [PMID: 25642337 DOI: 10.3978/j.issn.2078-6891.2014.054] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
101 Wu AJ, Goodman KA. Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation: are we there yet? J Gastrointest Oncol 2015;6:53-9. [PMID: 25642338 DOI: 10.3978/j.issn.2078-6891.2014.099] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
102 Fakhrian K, Ordu AD, Lordick F, Theisen J, Haller B, Omrčen T, Molls M, Nieder C, Geinitz H. Long-term outcomes of trimodality treatment for squamous cell carcinoma of the esophagus with cisplatin and/or 5-FU: more than 20 years' experience at a single institution. Strahlenther Onkol 2014;190:1133-40. [PMID: 25015426 DOI: 10.1007/s00066-014-0711-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
103 Shaikh T, Ruth K, Scott WJ, Burtness BA, Cohen SJ, Konski AA, Cooper HS, Astsaturov I, Meyer JE. Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer. Ann Thorac Surg. 2015;99:270-276. [PMID: 25440267 DOI: 10.1016/j.athoracsur.2014.08.033] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
104 Duan XF, Tang P, Yu ZT. Neoadjuvant chemoradiotherapy for resectable esophageal cancer: an in-depth study of randomized controlled trials and literature review. Cancer Biol Med. 2014;11:191-201. [PMID: 25364580 DOI: 10.7497/j.issn.2095-3941.2014.03.005] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
105 Tong YS, Zhou XL, Wang XW, Wu QQ, Yang TX, Lv J, Yang JS, Zhu B, Cao XF. Association of decreased expression of long non-coding RNA LOC285194 with chemoradiotherapy resistance and poor prognosis in esophageal squamous cell carcinoma. J Transl Med. 2014;12:233. [PMID: 25169763 DOI: 10.1186/s12967-014-0233-y] [Cited by in Crossref: 57] [Cited by in F6Publishing: 64] [Article Influence: 7.1] [Reference Citation Analysis]
106 Huang RW, Chao YK, Wen YW, Chang HK, Tseng CK, Chan SC, Liu YH. Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma. World J Surg Oncol 2014;12:170. [PMID: 24885430 DOI: 10.1186/1477-7819-12-170] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
107 Siddiqui FA, Atkins KM, Diggs BS, Thomas CR Jr, Hunter JG, Dolan JP. Overall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer. J Gastrointest Oncol 2014;5:86-91. [PMID: 24772335 DOI: 10.3978/j.issn.2078-6891.2014.014] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
108 Peixoto RD, Cheung WY, Lim HJ. Perioperative chemotherapy for gastroesophageal cancer in British Columbia: a multicentre experience. Curr Oncol 2014;21:77-83. [PMID: 24764696 DOI: 10.3747/co.21.1788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
109 Maskey D, Yousefi S, Schmid I, Zlobec I, Perren A, Friis R, Simon HU. ATG5 is induced by DNA-damaging agents and promotes mitotic catastrophe independent of autophagy. Nat Commun. 2013;4:2130. [PMID: 23945651 DOI: 10.1038/ncomms3130] [Cited by in Crossref: 102] [Cited by in F6Publishing: 92] [Article Influence: 12.8] [Reference Citation Analysis]
110 Ajani JA, Xiao L, Roth JA, Hofstetter WL, Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, Lee JH, Bhutani MS, Eid A, Yao JC, Phan AP, Halpin A, Suzuki A, Taketa T, Thall PF, Swisher SG. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 2013;24:2844-9. [PMID: 23975663 DOI: 10.1093/annonc/mdt339] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 6.7] [Reference Citation Analysis]
111 Makuuchi Y, Honda K, Osaka Y, Kato K, Kojima T, Daiko H, Igaki H, Ito Y, Hoshino S, Tachibana S. Soluble interleukin-6 receptor is a serum biomarker for the response of esophageal carcinoma to neoadjuvant chemoradiotherapy. Cancer Sci. 2013;104:1045-1051. [PMID: 23648090 DOI: 10.1111/cas.12187] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
112 Pietrantonio F, Biondani P, Ciurlia E, Fanetti G, Tessari A, Bertarelli G, Bossi I, Musella V, Melotti F, Di Bartolomeo M, Valvo F, Pellegrinelli A, Milione M, Perrone F, de Braud F. Role of BAX for outcome prediction in gastrointestinal malignancies. Med Oncol 2013;30:610. [PMID: 23700226 DOI: 10.1007/s12032-013-0610-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
113 Liu J, Yue J, Xing L, Yu J. Present status and progress of neoadjuvant chemoradiotherapy for esophageal cancer. Front Med. 2013;7:172-179. [PMID: 23681891 DOI: 10.1007/s11684-013-0268-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
114 Chen X, Ying Z, Lin X, Lin H, Wu J, Li M, Song L. Acylglycerol kinase augments JAK2/STAT3 signaling in esophageal squamous cells. J Clin Invest 2013;123:2576-89. [PMID: 23676499 DOI: 10.1172/JCI68143] [Cited by in Crossref: 44] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
115 Konieczny A, Meyer P, Schnider A, Komminoth P, Schmid M, Lombriser N, Weishaupt D. Accuracy of multidetector-row CT for restaging after neoadjuvant treatment in patients with oesophageal cancer. Eur Radiol. 2013;23:2492-2502. [PMID: 23645329 DOI: 10.1007/s00330-013-2844-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
116 Fujiwara H, Shiozaki A, Furutani A, Yoneda M, Kubota T, Komatsu S, Ichikawa D, Okamoto K, Murayama Y, Kuriu Y, Ikoma H, Nakanishi M, Ochiai T, Otsuji E. Time course of serum C-reactive protein levels during induction chemoradiotherapy and its correlation with treatment response and survival in patients with advanced esophageal squamous cell carcinoma. Mol Clin Oncol 2013;1:558-64. [PMID: 24649211 DOI: 10.3892/mco.2013.84] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
117 Chen Z, Saad R, Jia P, Peng D, Zhu S, Washington MK, Zhao Z, Xu Z, El-Rifai W. Gastric adenocarcinoma has a unique microRNA signature not present in esophageal adenocarcinoma. Cancer. 2013;119:1985-1993. [PMID: 23456798 DOI: 10.1002/cncr.28002] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
118 Yang H, Fu JH. Progress in surgery-based multimodality therapy for resectable esophageal cancer. Shijie Huaren Xiaohua Zazhi 2012; 20(35): 3471-3475 [DOI: 10.11569/wcjd.v20.i35.3471] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
119 Tejani MA, Burtness BA. Multi-modality therapy for cancer of the esophagus and GE junction. Curr Treat Options Oncol 2012;13:390-402. [PMID: 22592595 DOI: 10.1007/s11864-012-0193-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
120 Lordick F, Hölscher AH, Haustermans K, Wittekind C. Multimodal treatment of esophageal cancer. Langenbecks Arch Surg 2013;398:177-87. [PMID: 22971784 DOI: 10.1007/s00423-012-1001-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
121 Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 2012;23:2638-42. [PMID: 22831985 DOI: 10.1093/annonc/mds210] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 4.7] [Reference Citation Analysis]
122 Rahma OE, Greten TF, Duffy A. Locally advanced cancer of the esophagus, current treatment strategies, and future directions. Front Oncol 2012;2:52. [PMID: 22655277 DOI: 10.3389/fonc.2012.00052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
123 Pipas JM, Zaki BI, McGowan MM, Tsapakos MJ, Ripple GH, Suriawinata AA, Tsongalis GJ, Colacchio TA, Gordon SR, Sutton JE. Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma. Ann Oncol. 2012;23:2820-2827. [PMID: 22571859 DOI: 10.1093/annonc/mds109] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
124 Shibata T, Kokubu A, Saito S, Narisawa-Saito M, Sasaki H, Aoyagi K, Yoshimatsu Y, Tachimori Y, Kushima R, Kiyono T, Yamamoto M. NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia 2011;13:864-73. [PMID: 21969819 DOI: 10.1593/neo.11750] [Cited by in Crossref: 132] [Cited by in F6Publishing: 129] [Article Influence: 13.2] [Reference Citation Analysis]
125 Pan JY, Ajani JA, Gu J, Gong Y, Qin A, Hung M, Wu X, Izzo JG. Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation. Cancer 2012;118:4346-53. [PMID: 22213102 DOI: 10.1002/cncr.26581] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
126 Power DG, Ilson DH. Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers. Ther Adv Med Oncol 2009;1:145-65. [PMID: 21789119 DOI: 10.1177/1758834009347323] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
127 Predina JD, Judy B, Aliperti LA, Fridlender ZG, Blouin A, Kapoor V, Laguna B, Nakagawa H, Rustgi AK, Aguilar L, Aguilar-Cordova E, Albelda SM, Singhal S. Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models. Cancer Gene Ther 2011;18:871-83. [PMID: 21869822 DOI: 10.1038/cgt.2011.56] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
128 Tercioti Junior V, Lopes LR, Coelho Neto Jde S, Carvalheira JB, Andreollo NA. Local effectiveness and complications of neoadjuvant therapy in esophageal squamous cell carcinoma: radiotherapy versus chemoradiotherapy. Rev Col Bras Cir 2011;38:227-34. [PMID: 21971855 DOI: 10.1590/s0100-69912011000400005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
129 Wolf MC, Stahl M, Krause BJ, Bonavina L, Bruns C, Belka C, Zehentmayr F. Curative treatment of oesophageal carcinoma: current options and future developments. Radiat Oncol. 2011;6:55. [PMID: 21615894 DOI: 10.1186/1748-717x-6-55] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
130 Fields RC, Strong VE, Gönen M, Goodman KA, Rizk NP, Kelsen DP, Ilson DH, Tang LH, Brennan MF, Coit DG. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma. Br J Cancer. 2011;104:1840-1847. [PMID: 21610705 DOI: 10.1038/bjc.2011.175bjc2011175] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
131 Fields RC, Strong VE, Gönen M, Goodman KA, Rizk NP, Kelsen DP, Ilson DH, Tang LH, Brennan MF, Coit DG. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma. Br J Cancer. 2011;104:1840-1847. [PMID: 21610705 DOI: 10.1038/bjc.2011.175] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 5.7] [Reference Citation Analysis]
132 Yoon HH, Catalano PJ, Murphy KM, Skaar TC, Philips S, Powell M, Montgomery EA, Hafez MJ, Offer SM, Liu G. Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group. BMC Cancer. 2011;11:176. [PMID: 21586140 DOI: 10.1186/1471-2407-11-176] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
133 De Vita F, Orditura M, Martinelli E, Vecchione L, Innocenti R, Sileni VC, Pinto C, Di Maio M, Farella A, Troiani T. A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. Br J Cancer. 2011;104:427-432. [PMID: 21245865 DOI: 10.1038/sj.bjc.6606093] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
134 Ott K, Lordick F, Blank S, Büchler M. Gastric cancer: surgery in 2011. Langenbecks Arch Surg 2011;396:743-58. [PMID: 21234760 DOI: 10.1007/s00423-010-0738-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
135 Marjanovic G, Schricker M, Walch A, zur Hausen A, Hopt UT, Imdahl A, Makowiec F. Detection of lymph node involvement by cytokeratin immunohistochemistry is an independent prognostic factor after curative resection of esophageal cancer. J Gastrointest Surg. 2011;15:29-37. [PMID: 20976569 DOI: 10.1007/s11605-010-1359-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
136 Forastiere AA. Multimodality treatment of esophagus cancer: current status and future perspectives in the United States. Esophagus 2010;7:1-6. [DOI: 10.1007/s10388-009-0226-8] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
137 Bain GH, Petty RD. Predicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers. Oncologist 2010;15:270-84. [PMID: 20203174 DOI: 10.1634/theoncologist.2009-0293] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
138 Starling N, Okines A, Cunningham D, Allum W, Wotherspoon A, Benson M, Thompson J, Thomas J, Brown G, Riddell A, Stavridi F, Ashley S, Oates J, Chau I. A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. Br J Cancer. 2009;100:1725-1730. [PMID: 19436301 DOI: 10.1038/sj.bjc.6605070] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
139 Donahue JM, Nichols FC, Li Z, Schomas DA, Allen MS, Cassivi SD, Jatoi A, Miller RC, Wigle DA, Shen KR, Deschamps C. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg 2009;87:392-8; discussion 398-9. [PMID: 19161745 DOI: 10.1016/j.athoracsur.2008.11.001] [Cited by in Crossref: 179] [Cited by in F6Publishing: 177] [Article Influence: 13.8] [Reference Citation Analysis]
140 Crane SJ, Locke GR 3rd, Harmsen WS, Zinsmeister AR, Romero Y, Talley NJ. Survival trends in patients with gastric and esophageal adenocarcinomas: a population-based study. Mayo Clin Proc 2008;83:1087-94. [PMID: 18828967 DOI: 10.4065/83.10.1087] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
141 Gines A, Cassivi SD, Martenson JA Jr, Schleck C, Deschamps C, Sinicrope FA, Alberts SR, Murray JA, Zinsmeister AR, Vazquez-Sequeiros E, Nichols FC 3rd, Miller RC, Quevedo JF, Allen MS, Alexander JA, Zais T, Haddock MG, Romero Y. Impact of endoscopic ultrasonography and physician specialty on the management of patients with esophagus cancer. Dis Esophagus 2008;21:241-50. [PMID: 18430106 DOI: 10.1111/j.1442-2050.2007.00766.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
142 Kostakoglu L. FDG-PET Evaluation of Response to Treatment. PET Clin 2008;3:37-75. [PMID: 27158146 DOI: 10.1016/j.cpet.2008.09.001] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
143 Ajani JA. Can we understand the clinical biology of gastric cancer and exploit it? May be, but it is a challenge! Ann Surg Oncol 2007;14:3290-2. [PMID: 17932722 DOI: 10.1245/s10434-007-9575-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
144 van de Schoot L, Romme EA, van der Sangen MJ, Creemers GJ, van Lijnschoten G, van Driel OJ, Rutten HJ, Nieuwenhuijzen GA. A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer. Ann Surg Oncol. 2008;15:88-95. [PMID: 17896144 DOI: 10.1245/s10434-007-9582-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
145 Chang EY, Li X, Jerosch-Herold M, Priest RA, Enestvedt CK, Xu J, Springer CS, Jobe BA. The evaluation of esophageal adenocarcinoma using dynamic contrast-enhanced magnetic resonance imaging. J Gastrointest Surg. 2008;12:166-175. [PMID: 17768665 DOI: 10.1007/s11605-007-0253-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
146 Wilson M, Rosato EL, Chojnacki KA, Chervoneva I, Kairys JC, Cohn HE, Rosato FE, Berger AC. Prognostic significance of lymph node metastases and ratio in esophageal cancer. J Surg Res. 2008;146:11-15. [PMID: 18028955 DOI: 10.1016/j.jss.2007.07.028] [Cited by in Crossref: 64] [Cited by in F6Publishing: 70] [Article Influence: 4.3] [Reference Citation Analysis]
147 Griffiths EA, Pritchard SA, Mapstone NP, Welch IM. Emerging aspects of oesophageal and gastro-oesophageal junction cancer histopathology - an update for the surgical oncologist. World J Surg Oncol. 2006;4:82. [PMID: 17118194 DOI: 10.1186/1477-7819-4-82] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
148 Dawson SJ, Michael M, Biagi J, Foo KF, Jefford M, Ngan SY, Leong T, Hui A, Milner AD, Thomas RJ. A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. Invest New Drugs. 2007;25:123-129. [PMID: 17053988 DOI: 10.1007/s10637-006-9016-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
149 Fiore FD, Lecleire S, Rigal O, Galais MP, Soussan EB, David I, Paillot B, Jacob JH, Michel P. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol 2006; 12(26): 4185-4190 [PMID: 16830371 DOI: 10.3748/wjg.v12.i26.4185] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.0] [Reference Citation Analysis]
150 van Meerten E, Muller K, Tilanus HW, Siersema PD, Eijkenboom WM, van Dekken H, Tran TC, van der Gaast A. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer 2006;94:1389-94. [PMID: 16670722 DOI: 10.1038/sj.bjc.6603134] [Cited by in Crossref: 82] [Cited by in F6Publishing: 75] [Article Influence: 5.1] [Reference Citation Analysis]